# Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma

> **NCT03602833** · PHASE1,PHASE2 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 12 (actual)

## Conditions studied

- Soft-tissue Sarcoma

## Interventions

- **DRUG:** Compound 451238

## Key facts

- **NCT ID:** NCT03602833
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602833, "Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03602833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*